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SUMMARY
Interest in targeted disease prevention has stimulated development of models that
assign risks to individuals, using their personal covariates. We need to evaluate these
models, and to quantify the gains achieved by expanding a model with additional
covariates. We describe several performance measures for risk models, and show how
they are related. Application of the measures to risk models for hypothetical
populations and for postmenopausal US women illustrate several points. First, model
performance is constrained by the distribution of true risks in the population. This
complicates the comparison of two models if they are applied to populations with
different covariate distributions. Second, the Brier Score and the Integrated
Discrimination Improvement (IDI) are more useful than the concordance statistic for
quantifying precision gains obtained from model expansion. Finally, these precision
gains are apt to be small, although they may be large for some individuals. We
propose a new way to identify these individuals, and show how to quantify how much
they gain by measuring the additional covariates. Those with largest gains could be
targeted for cost-efficient covariate assessment.
Keywords: absolute risk, Brier score, calibration, concordance, discrimination,
personalized disease prevention, precision, resolution, risk model
1. INTRODUCTION
People want to know their risks of future adverse health outcomes, to help weigh
the pros and cons of risk-reducing interventions. A person’s risk p is determined by
his values z of a set of risk-determining covariates: p = ξ (z) . Since the full set of
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covariates z is seldom known, a risk model uses a subset x of the covariates to assign a
risk r = γ (x) . The assigned risks of a good risk model are accurate (i.e., agree with
outcome prevalences within subgroups of the population) and precise (i.e., able to
discriminate those with different true risks). To evaluate risk models, we consider
three measures of model performance, developed for use in meteorology, economics
and psychology [1-4]. The Brier score evaluates both the accuracy and the precision
of assigned risks. In contrast, the risk-outcome (RO) correlation and the commonly
used concordance [5] evaluate only the precision of a risk model.
An important issue is how much the precision of a risk model can be improved by
expanding it with additional covariates. The precision component of the Brier score is
particularly useful for resolving this issue. We show how to use it to identify
individuals who may benefit substantially from such expansion, even when the overall
gain in the population is small. We also show that precision gains are constrained by
the distribution ϕ (z) of covariates in the population to which the original and
expanded models are applied. This constraint complicates comparison of two risk
models, especially if they have been applied to two different populations.
2. POPULATION RISKS AND RISKS MODELS
2.1 Population Risks
Consider a population of women aged 50 years who are at risk of developing
breast cancer within a ten year period. Each woman has an unknown probability p of
this outcome, which depends on covariates z that determine her breast cancer hazard
rate and her mortality rate. The covariates z may include continuous and/or discrete
components, and thus the risks p may assume continuous or discrete values. In
practise, however, continuous covariates and risks are grouped into finitely many
discrete categories, and here we shall represent all risks as discrete.
Some of the covariates may be unknown. For example, a woman’s risk may
depend on an unknown combination of her genetic inheritance and hormonal
exposures. Women with different covariates z may have the same risk p. For instance,
a low breast cancer risk may pertain to one woman whose covariates indicate low risks
for both breast cancer and competing causes of death during the period, and to
another whose covariates indicate high breast cancer risk but also high mortality risk.
The population covariate distribution ϕ (z) determines the population risk distribution
f (p) via the relation
f (p) =
∑
z:ξ(z)=p
ϕ (z) . (1)
The mean pi of the risk distribution f specifies the prevalence of the outcome in the
population. The variance σ2 of f specifies the degree of risk heterogeneity in the
population.
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Figure 1 shows two risk distributions, both with mean 10%, that provide bounds
on population risk heterogeneity for all populations with outcome prevalence pi = 10%.
At one extreme, the ”constant” distribution c (left panel) assigns all mass to the mean
risk pi:
c (p) = 1 if p = pi (2)
= 0 else.
Under this distribution, all in the population have the same risk pi, and the risk
variance σ2 = 0. Thus the variance of this distribution gives a lower bound on that of
any distribution with mean pi. At the other extreme, the deterministic distribution d
(right panel) assigns mass 1− pi to p = 0 and mass pi to p = 1:
d (p) = 1− pi if p = 0 (3)
= pi if p = 1.
Under this distribution, the outcome occurs deterministically, with probability one in
a fraction pi of the population, and with probability zero in the remainder. The risk
variance is σ2 = pi (1− pi), which gives an upper bound on the variance of any risk
distribution with mean pi. When the mean risk is pi = 10%, for example, the maximum
standard deviation of risks is 30%.
Since the variance σ2 = 0 of distribution (2) is a lower bound on σ2, and that of
distribution (3) is an upper bound, we have
0 ≤ σ2 ≤ pi (1− pi) . (4)
2.2 Risk Models
The complete covariates z that determine a woman’s breast cancer risk are not
known. Therefore we use measured covariates x = κ (z) , and outcomes obtained from
cohort data to develop a risk model γ. It assigns to all women with covariates x a risk
γ(x) = r, 0 < r < 1. Then, given a woman’s measured covariates, we approximate her
unknown true risk p by her assigned risk r.
The distribution of a model’s assigned risks is g (r) =
∑
ϕ (z) , where the
summation is taken over {z : γ [k (z)] = r} , and the joint distribution of true risk P
and assigned risk R is fP,R (p, r) =
∑
ϕ (z) , with summation taken over
{z : ξ (z) = p & γ [k (z)] = r}. The distribution of true risks among individuals
assigned risk r is
fP |R (p|r) =
fP,R (p, r)
g (r)
. (5)
The mean pi (r) of this distribution is the outcome prevalence in the subgroup of
individuals with assigned risk r [6].
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The variance of the outcome prevalences pi (r) across risk groups equals their
covariance with individual outcomes y, as shown in Appendix equation (22). This
covariance is bounded by the covariance between individual outcomes and true risks:
covY,R [y, pi (r)] = varR [pi (r)] ≤ covY,P (y, p) = σ2. (6)
Combining inequalities (4) and (6) gives an ordering for the variances of outcome
prevalences in assigned and true risk groups:
0 ≤ varR [pi (r)] ≤ σ2 ≤ pi (1− pi) . (7)
We shall see that the variance of outcome prevalences across a model’s assigned risk
groups determines its precision. The inequalities (7) indicate that this variance is
bounded by the heterogeneity of true risks in the population (which the investigator
cannot control).
To illustrate this point with a simple hypothetical example, consider the risk
distributions in panels (a) and (b) of Figure 2 for two populations with appreciably
different distributions of risk-determining covariates z = z0, z1, z2, z3. Specifically, the
distribution of z depends on a parameter α in the unit interval, and Population A
corresponds to α = 0.2 while Population B corresponds to α = 0.8. Both risk
distributions have mean pi = 10%, and both sets of risks range from 2% to 74%.
However the variance of risks is much larger for Population B (σ2 = 2.83%) than for
Population A (σ2 = 0.30%). Now consider a model that assigns risks using only the
first two of the covariates z0, z1, z2, z3. Panels (c) and (d) show the distributions g (r)
of outcome prevalences pi (r) within the five risk groups of this model. The variance of
outcome prevalences in Population A is varR [pi (r)] = 0.24%, which by (7) is bounded
by the variance σ2 = 0.30% of true risks. In contrast, the variance varR [pi (r)] in
Population B is 2.57%, with the more relaxed upper bound of 2.83%. Note that, in
both populations, omitting covariates results in rearranging the nine risk groups of
panels (a) and (b) into the five groups of panels (c) and (d), with loss of precision. In
particular, the group in panel (c) with outcome prevalence of 33% consists of some
individuals whose true risk is 26%, others whose true risk is 42% and still others whose
true risk is as high as 74%. (The covariate distribution ϕ (z) , the relation p = ξ (z)
and the outcome prevelances pi (r) for this example are given in the Appendix.)
3. PERFORMANCE MEASURES FOR RISK MODELS
What attributes do we want in a risk model? First, we want the model to assign
each individual an accurate risk, i.e., one that agrees well with his or her true risk.
How do we measure accuracy when we don’t know this true risk? Since a person’s true
risk is the probability of developing the outcome, his or her assigned risk r should
agree with the outcome prevalence pi (r) (i.e., the mean true risk) among all those
assigned risk r. A model’s calibration describes this agreement.
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However a model, even though well-calibrated, should not assign a single risk to a
group of individuals whose true risks vary substantially. Such a group might consist of
two subgroups, one containing individuals at high risk and the other individuals at low
risk. Overall, their outcome prevalence might agree with their assigned risk, but
important risk-determining covariates would not be reflected in the model. Thus the
second desirable attribute of a model is its precision (also called resolution or
discrimination), which reflects its ability to sort the population into subgroups with
different true risks.
In considering a model’s calibration and precision, it is useful to compare it to a
perfect model (Model P) that assigns each individual his or her true risk: r = p. The
risks of Model P are those people would receive if we could measure their complete
covariates z, and could correctly specify the relation p = ξ (z) between covariates and
risk. The distribution of assigned risks for Model P is just g (r) = f (r) .
3.1 Model Calibration
The calibration of a risk model describes how well its assigned risks agree with
outcome prevalences in subgroups of the population. The calibration bias in a
subgroup of individuals assigned a given risk r is the difference r − pi (r) between
assigned risk and outcome prevalence in the subgroup. A risk model is said to be
well-calibrated if its calibration bias is zero for all assigned risks r. Calibration biases
are displayed in an attributes diagram [7], which is a plot of the points (r, pi (r)) for
given assigned risks r. For well-calibrated models, such as the perfect Model P, these
points lie on the 45-degree line.
To illustrate calibration, we return to the example of Figure 2. A risk model
based on the two covariates z0, z1 can assign each of its five subgroups any risk
between 0 and 1. However it is well-calibrated to the population only if it assigns
them risks equal to their outcome prevalences. Thus a model that is well calibrated to
Population A assigns the five risks shown on the abscissa of panel (c) of Figure 2.
These are determined by Appendix formula (20) with the parameter α = 0.2. If these
same risks were assigned to individuals in Population B, the model would show the
calibration biases displayed in the attribute diagram in the upper panel of Figure 3.
These biases occur because Populations A and B have different distributions of the
two unmeasured risk-determining covariates whose distributions are determined by α,
and thus they have different outcome prevalences within assigned risk groups. Note
that the largest biases occur among those at highest risk.
A useful summary of a model’s accuracy is its overall calibration bias, whose
square is the average of the squared biases r − pi (r) (vertical distances in Figure 3),
weighted by the proportions g (r) of individuals in the assigned risk groups:
Bias2g = ER
{
[r − pi (r)]2
}
=
∑
0≤r≤1 g (r) [r − pi (r)]
2 . (8)
The overall calibration bias for the data in the upper panel of Figure 3 is
Biasg = 8.9%.
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3.2 Model Precision
We consider three closely related precision measures: the Brier precision loss, the
risk-outcome correlation coefficient, and the concordance. These measures depend on
the variances of outcome prevalences pi (r) in subgroups assigned the same risk r.
They do not depend on the variance of the actual assigned risks (which may vary
considerably). Thus using poorly calibrated assigned risks to measure a model’s
precision can be misleading.
A model’s Brier score [1], also called its mean probability score [3], is the mean
squared error between individual outcomes and risk:
BSg = EY,R
[
(y − r)2
]
.
The Brier score measures both the accuracy and the precision of a model. To see this,
we decompose it as
BSg = Bias2g + PLg. (9)
Here Biasg is the model’s calibration bias defined by (8), and
PLg = pi (1− pi)− varR [pi (r)] (10)
is its precision loss. PLg is the difference between the maximum risk variance
pi (1− pi) for a deterministic outcome and the variance of outcome prevalences pi (r)
across population subgroups with specific assigned risks r. The larger the latter
variance, the smaller the precision loss and the more precise the model. The Appendix
contains a proof of the decomposition (9), due to Murphy [2].
A model’s Brier precision loss is closely related to its risk-outcome (RO)
correlation coefficient
ρg =
covY,R [y, pi (r)]√
varY (y) varR [pi (r)]
=
√
varR [pi (r)]
pi (1− pi) . (11)
The second equality in (11) follows from (6). Combining (11) and (10) we see that the
Brier precision loss is
PLg =
(
1− ρ2g
)
pi (1− pi) . (12)
Inequality (7) shows that a model’s precision loss and RO correlation are both
bounded by their counterparts for the unknown perfect model. In particular,
0 ≤ ρg ≤ ρf ≤ 1,
where ρf is the RO correlation coefficient for the perfect model, and
0 ≤ pi (1− pi)− σ2 ≤ PLg ≤ pi (1− pi) ,
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where σ2 is the population variance of the true risks. The values of ρg and PLg
approach their optimal levels as the risk model captures increasingly many of the
risk-determining covariates.
The second and third columns of Table 1 show Brier precision loss and RO
correlation coefficient for a model applied to populations A and B of Figure 2, using
the two covariates z0, z1 (Model 1). Comparison of these values with those of the
perfect Model P shows that the poor precision of Model 1 is caused more by
homogeneity of true risks than loss of covariate information. For example, the RO
correlation coefficients for Model 1 (16.3% for Population A and 53.4% for Population
B) are not far from their optimal values 18.1% and 56.1% for these two populations,
given by the perfect model.
The most widely used precision measure for health risk models is the concordance,
also called the area under the receiver operating characteristic curve, or
area-under-the-curve (AUC). To describe it, we introduce the conditional distributions
of assigned risk among those who do and do not develop the outcome:
hy (r) = Pr (R = r|Y = y) = g (r) [pi (r)]
y [1− pi (r)]1−y
piy (1− pi)1−y , y = 0, 1. (13)
The concordance is the probability that a risk chosen from the distribution h1 exceeds
one chosen from h0:
ζg =
∑
0≤r≤1H1 (r)h0 (r) (14)
[5,8]. Here the cumulative distribution H1 (r) = 12h1 (r) +
∑
u>r h1 (u) when h is
discrete, and H1 (r) =
∫ 1
r h1 (u) du when h is continuous. The concordance is
invariant under any rank-preserving transformation of the assigned risks. Thus any
set of assigned risks whose ranks agree with those of the outcome prevalences pi (r) has
the same concordance as that of a well-calibrated risk model. The concordance
achieves its minimum of 50% when the risk distribution is the constant one c (p) of
(2), and its maximum of 100% when the model is perfect and the true risk distribution
f (p) = d (p) of (3).
As seen in Table 1, the concordance of Model 1 is 59.4% for Population A and
80.6% for Population B. For comparison, concordances of the perfect model for these
two populations are 60.3% and 83.3%, respectively.
Since the concordance is a function of the conditional distributions h1 (r) and
h0 (r), it is most easily interpreted as a retrospective assessment of how well a model
discriminates the risks of those with and without the outcome. Indeed, the model’s
Brier precision loss and RO correlation coefficient also can be interpreted this way. To
see this, note from (13) and (11) that the squared RO correlation coefficient can be
written as the mean of the outcome prevalences pi (r) , averaged over the assigned risk
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subgroups of those who develop the outcome, minus the corresponding mean in those
who do not:
ρ2g = ER|Y [pi (r) |y = 1]− ER|Y [pi (r) |y = 0]
≡
∑
r
pi (r) [h1 (r)− h0 (r)] . (15)
This representation has motivated the name Integrated Discrimination for ρ2g [9]. The
Brier precision loss shares this retrospective interpretation, since it is proportional to
1− ρ2g by (12). However the interpretation is not particularly useful for health risk
assessment, whose goal is to classify individuals prospectively into risk strata requiring
different preventive strategies [10-12]. To their advantage, the Brier precision loss and
RO correlation also can be interpreted prospectively as measures of the extent to which
individuals with different true risks are grouped together and assigned a common risk.
This interpretation has heuristic value for individual risk assessment [13].
3.3 Comparing Different Risk Models
Let x1 and x2 represent two sets of risk-related covariates measured on the same
population, and suppose we have developed risk models based on each of them, with
assigned risks γ1 (x1) = r1 and γ2 (x2) = r2 (Models 1 and 2 respectively). Often x2
consists of x1 plus additional covariates. For example, the covariates x1 might consist
of known breast cancer risk factors [14] and the covariates x2 might augment x1 with
breast density measurements [15] or the genotypes of certain susceptibility variants
[16]. An important issue is how to compare the performances of the two models,
which may differ in both calibration accuracy and precision.
The Brier score is particularly useful for such comparison. To see this, we use
(9-10) to write the difference in Brier scores for two models as
BSg1 −BSg2 =
(
Bias21 −Bias22
)
+ (PLg1 − PLg2)
=
(
Bias21 −Bias22
)
+ {varR2 [pi (r2)]− varR1 [pi (r1)]} . (16)
Here the subscripts 1 and 2 refer to the two risk models. The first summand of (16) is
the gain or loss of squared calibration bias in Model 2 compared with Model 1. The
second summand, called the Brier precision difference, is the variance of outcome
prevalences across subgroups assigned common risks by Model 2, minus the
corresponding variance for Model 1. From (12) we see that it is proportional to the
difference in the two models’ squared RO correlation coefficients:
PL1 − PL2 = varR2 [pi (r2)]− varR1 [pi (r1)] = pi (1− pi)
(
ρ2g2 − ρ2g1
)
. (17)
The difference ρ2g2 − ρ2g1 has been called the Integrated Discrimination Improvement
(IDI) by Pencina et al (2008), who propose it to measure the precision gained by
adding covariates to a model. Both the IDI and the Brier precision difference compare
the models’ abilities to sort individuals into groups having different true risks.
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Comparing calibration. We illustrate the calibration component of the Brier score
difference (17) using the two populations in Figure 2 whose true risks are determined
by the four covariates z0, z1, z2, z3. Suppose we expand a model based on z0, z1 (Model
1) by including the additional covariate z2. Panels (e) and (f) of Figure 2 show the
distributions of outcome prevalences within the seven assigned risk groups of the
expanded model (Model 2). These are given by Appendix equation (21). Consider the
calibration biases that would result if Models 1 and 2 were each well-calibrated to
Population A but applied to Population B, as shown in Figure 3. The overall
calibration bias for Model 2 is 5.5% (panel (b)), an improvement in accuracy compared
to the value 8.9% for Model 1 (panel (a)). In general, however, expanding a risk model
with additional covariates need not reduce its calibration bias. In Population B, for
instance, Model 2 might assign biased risks to each of its two risk groups having
outcome prevalences 38.8% and 67.6% (panel (f) in Figure 2), whereas Model 1 might
assign a well-calibrated risk of 61.8% to the combined group in panel (d).
A more informative comparison of the calibration biases of two risk models for a
population would focus on individuals assigned a common risk by each of the two
models. To make such a comparison, we embed both models in a common
well-calibrated model, which we call their cross-classified model. This model
partitions the population into subgroups of individuals who receive a common assigned
risk from each of the two models. To describe it, consider in Figure 4 how Population
B is partitioned into five risk groups by a model based on two covariates (Model 1)
and into seven risk groups by an expanded model that uses an additional covariate
(Model 2). Each risk group (denoted by a pie wedge) is labeled with its outcome
prevalence. Note that some individuals assigned different risks by Model 1 receive the
same risk by Model 2. This shows that adding covariates to a model need not yield a
more refined partition of the population. To obtain the cross-classified model (Model
C), we cross-classify individuals according to the risks they receive by the two models,
and then assign each of the resulting subgroups a common risk equal to the outcome
prevalence in that group. Thus the cross-classified model assigns to those with risk r1
from Model 1 and risk r2 from Model 2 the risk pi (r1, r2) which is their outcome
prevalence (i.e., their mean true risk). Figure 4 also shows the partition of Population
B induced by the cross-classified model for Models 1 and 2.
We can now compare the models’ biases in each of the nine risk groups of the
cross-classified model. Figure 5 shows the outcome prevalences in these nine risk
groups, and the risks assigned by the two models when each is well-calibrated to
Population A but applied to Population B. Both models exhibit substantial
downward bias in the group with the highest outcome prevalence, with at most small
bias in the five groups at lowest risk. Moreover compared to Model 1, the expanded
Model 2 is less biased in groups 7 and 9, but more biased in groups 6 and 8.
Comparing precision. While expanding a model with additional covariates may
actually decrease its overall accuracy, in general, such expansion will increase its
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precision. The issue is whether the precision increase is large enough to warrant the
cost of measuring and modeling the additional covariates. To illustrate this point,
consider the precision measures shown in Table 1 for models using two and three
covariates of the populations of Figure 2 (Models 1 and 2 respectively). Note that,
relative to Model 1, Model 2 yields only small gains in precision for individuals in
Population A: the Brier precision difference is only 0.03%, the RO correlation
coefficient increases by only 0.9%, and the concordance increases by only 0.5%. The
gains are slightly larger for the more heterogeneous Population B: 0.13% in Brier
precision difference, 1.3% in RO correlation, and 1.5% in concordance. Nevertheless,
the overall precision gain from expanding Model 1 with additional covariates is small
by any measure, for each population.
This example shows that the overall precision gain can be negligible, even though
the expanded model may be considerably more precise in certain subgroups of the
population [12]. This anomaly occurs because individuals with small risks, who
typically comprise most of the population, tend to benefit little from increased
precision, while the few with large risks have much to gain. Since the precision
measures are averages over the entire population, the small gains for the majority tend
to dominate the larger gains for a few. This problem can be addressed by creating
subgroup-specific measures of relative precision, where each subgroup consists of
individuals assigned a common risk by a given model (say, Model 1).
We use the Brier precision difference to describe how to find the Model 1 risk
groups that gain the most. The idea is to embed the two models in their common
well-calibrated cross-classified model, and then use the latter to evaluate the increased
precision for each risk group of Model 1. Specifically, we write the overall Brier
precision difference (17) between Models 1 and 2 in terms of differences from their
common cross-classified model:
PL1 − PL2 = (PL1 − PLE)− (PL2 − PLE) .
Equation (17) shows that the precision difference PL1 − PLE is the variance of
outcome prevalences across risk groups determined by the cross-classified model,
minus the corresponding variance for groups determined by Model 1:
PL1 − PLE = varR1,R2 [pi (r1, r2)]− varR1 [pi (r1)] .
We show in the Appendix that this difference is the average of subgroup-specific
variances:
PL1 − PLE = ER1
{
varR1,R2|R1 [pi (r1, r2) |r1]
}
=
∑
0≤r1≤1
g1 (r1) varR1,R2|R1 [pi (r1, r2) |r1] . (18)
The variance of outcome prevalences within the subgroup assigned a given risk r1,
denoted varR1,R2|R1 [pi (r1, r2) |r1] in (18), gives a measure of precision gain in this risk
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group. These variances (or their corresponding standard deviations) can be used to
determine those risk groups for whom measuring additional covariates has the greatest
benefit.
To illustrate this assessment, suppose we wish to determine the Model 1 risk
groups in Population B who gain most from the additional covariate used by Model 2.
Table 2 shows the ranges and standard deviations of outcome prevalences in the nine
subgroups determined by the cross-classified model, within each of the five risk groups
of population B assigned a common risk by Model 1. The precision gains, as measured
by these standard deviations, range from zero (in those assigned a risk of 10% by
Model 1) to 11.5% (in those assigned the highest risk of 61.8%). Thus the individuals
at highest risk gain substantially more precision from the additional covariate than do
other individuals. If this covariate were difficult to measure, it might be deemed
cost-efficient to do so only for those individuals to whom Model 1 assigns the highest
risks.
4. APPLICATION TO DATA
We illustrate the performance measures by application to two models for risk of
estrogen-receptor-positive (ER+) breast cancer among postmenopausal women. These
models were developed by Rosner et al [17] using data from the prospective Nurses
Health Study (NHS). The investigators identified 1559 ER+ breast cancer cases in
476,581 person-years of followup among postmenopausal women with a natural
menopause, giving a crude annual incidence rate of 1559/476,581 = 0.0021 cases per
woman per year. To illustrate the methods described here, we consider the ten-year
breast cancer risks induced by this incidence rate in a hypothetical cohort of
postmenopausal women aged 50 years with the same covariate distribution as the NHS
women. The annual death rate for US white women aged 50-59 years is 0.0053
deaths per woman per year [18]. This rate, combined with the breast cancer incidence
rate of 0.0021, yields a mean risk pi = 2.02% of developing ER+ breast cancer within
ten years. Because this risk is low, the maximum risk heterogeneity in this population
is also low: the standard deviation of risks is bounded above by√
.0202 (1− .0202) = 14.1%.
Rosner et al [17] developed a risk model based on each woman’s current age,
age at menarche, age at natural menopause, parity, ages at all births, history of benign
breast disease, history of breast cancer in a mother or sister, and years of use of
estrogen replacement therapy (Model 1). The investigators also expanded this model
by including one additional covariate representing estimated serum levels of
endogenous estradiol (Model 2). Table 4 of Rosner et al [17] presents case counts,
person-years of followup, and incidence rates within subgroups of the population
cross-classified by joint deciles of risk as assigned by Models 1 and 2. Here we used
these incidence rates and all-cause mortality rates to compute the ten-year breast
cancer risks shown in Table 3.
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Models 1 and 2 were calibrated to the NHS population, and we do not investigate
their potential biases if applied to a similar but independent cohort of US
postmenopausal women. Instead we assume that the probabilities shown in the joint
risk groups of Table 3 represent the mean true risks, i.e. the ten-year breast cancer
prevalences in each joint risk group. With this assumption, the 40 nonempty cells in
the interior of Table 3 represent the joint risk groups of the cross-classified model for
Models 1 and 2. From the row and column margins of Table 3 we calculate a standard
deviation for Model 1 risks of
{∑10
r1=1
0.1 [pi (r1)− 0.0202]
}1/2
= 1.04%, while that for
Model 2 risks is 1.22%. These values correspond to RO correlation coefficients of 3.1%
and 4.6%, respectively, and to a small overall Brier precision gain of .004%.
Which risk groups of Model 1 benefit most from the addition of endogenous
estradiol levels to the model? To answer this question, we refer to the last two
columns of Table 3, which show the range and standard deviation of the
cross-classified outcome prevalences within each of the ten Model 1 risk groups. The
smallest range is 0.7%− 1.0% in the first decile of Model 1, and the largest is
0.6%− 6.5% in the seventh decile. The standard deviations vary tenfold from 0.12% in
group 1 to 1.24% in group 9. (To calculate these standard deviations, we assumed that
within each decile of Model 1 risk, women were distributed in the same proportions as
the person-years of followup given by Rosner et al [17].) In this example, there are
modest benefits in prediction precision that these women might receive from adding a
serum estradiol measurement. Moreover, the absolute benefits do not vary appreciably
across risk groups determined by Model 1. These results are due in part to the
limited range of risks in this population, and may also reflect measurement error in
the estimated estradiol levels.
5. DISCUSSION
We have described the Brier score, the risk-outcome (RO) correlation, and the
concordance as performance measures for risk models that use personal covariates to
assign personal risks of a future adverse outcome. The Brier score is the sum of terms
representing calibration bias plus precision loss, while the RO correlation coefficient
and concordance measure only precision loss. Application of the measures to risk
models for two hypothetical populations and for postmenopausal women at risk of
breast cancer illustrates several points.
First, though an individual wanting to know his or her own personal risk for an
adverse outcome is not concerned with how a model performs for others in his
population, paradoxically, model performance is sensitive to the distribution of
covariates in the entire population. No risk model can be more precise than the ideal
perfect model that assigns the true risks to all in the population. In particular, a
homogeneous distribution of true risks induces poor precision values for all risk models
for that population, as noted by Cook [10]. Because of this strong dependence of
precision measures on the population risk distribution, comparing summary measures
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of model performance in different populations requires caution. For example, Table 1
shows that if we applied Model 1 to Population B and Model 2 to Population A, we
would conclude that Model 1 is superior to Model 2 by any precision measure, despite
the consistently better precision of Model 2 when both models are applied and
calibrated to the same population.
Evaluating precision in a single population also warrants caution if the models are
not well calibrated. This is because precision reflects how outcome prevalences vary
across the risk groups, and not how the assigned risks vary. Thus precision measures
based on the variances of poorly calibrated assigned risks can be misleading.
The calibration accuracy and precision of two risk models for a given population
can be compared using the difference in their values for an appropriate performance
measure. The Brier score difference is particularly useful because it is the sum of a
component that compares the accuracy of assigned risks, and a component that
compares their precision. Each of these two components has a meaningful prospective
interpretation for individuals seeking to know their own risks for a future adverse
outcome.
Nevertheless, all summary measures of model performance have two limitations.
First, because they depend on the population’s distribution of measured covariates,
they cannot be compared reliably across populations with different covariate
distributions. Second, the precision gained by adding covariates to a model may not
be uniform across all population subgroups. It may be large in certain subgroups,
while the overall gain may be small. Both these limitations can be addressed by
focusing on subgroup-specific performance measures. We have proposed a new
method for evaluating subgroup-specific gains or losses in both calibration and
precision by using one model compared to another. In particular, we propose
evaluating the precision gain within each risk group defined by one of the models, by
quantifying the spread of outcome prevalences across those cross-classified according to
joint risks from both models. This idea is similar in flavor to that of Cook [19], who
proposed evaluating the percentages of people who move to a different risk quantile
after additional covariate assessment. Knowing which subgroups gain the most
accuracy and precision in assigned risk can be useful for preventive efforts, because
these are the people with most to gain by enlarging the risk model to include the
covariates that distinguish their risks. This opportunity to evaluate subgroup-specific
performance improvement suggests the following strategy: evaluate gains within
assigned risk groups to determine those groups most likely to benefit from gathering
additional covariate information; then target them for such covariate assessment.
Further work is needed to develop and evaluate all personal risk models [20]. For
example, we need models and performance measures that accommodate multiple
correlated adverse outcomes. At present, outcomes are studied in isolation, although
preventive interventions typically affect risks for several outcomes [21]. In addition,
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most models assume that all individuals have the same age-specific mortality rates for
competing causes of death, despite large variation in these rates among the elderly
[22]. These issues should be addressed in future risk models and performance
measures. Finally, we need to understand how risk information is perceived by
patients and their physicians. Small improvements in the precision of assigned risks
are of little significance for personal preventive decisions, so we need to target those
with the largest potential gains.
APPENDIX
Risk distributions of Figure 2. The risks shown in panels (a) and (b) of
Figure 2 are determined by four covariates z0, z1, z2, z3, with z0 coded as −1, 0, 1, and
zj coded as 0, 1, j = 1, 2, 3. These covariates determine risk according to the rule
p = ξ (z) = 0.1 + 0.01z02z1+z2+z3 , z0 = −1, 0, (19)
= 0.1 + 0.08z02z1+z2+z3 , z0 = 1.
The distributions f (p) in the two panels are determined by the relation (1), where the
covariate distribution ϕ (z) = τ (z0)
∏3
i=1 α
zi (1− α)1−zi . Here τ (z0) = 0.8, 0.1, 0.1,
for z0 = −1, 0, 1, respectively. The value α = 0.2 gives the distribution for Population
A and α = 0.8 gives the one for Population B. The mean risk is 10% and the variance
is 7.2× 10−4 (1 + 3α)3 .
Panels (c) and (d) of Figure 2 show outcome prevalences within population
subgroups assigned common risks based on two of the four covariates: z0, z1 . These
prevalences are
pi [r1 (z0, z1)] =

0.1− .01 (1 + α)2 × 2z1 , z0 = −1
0.1, if z0 = 0
0.1 + .08 (1 + α)2 × 2z1 , z0 = 1
. (20)
Panels (e) and (f) of Figure 2 give outcome prevelances in the seven subgroups
determined by expanding a risk model based on z0, z1 (Model 1) to include z2. These
prevalences are
pi [r1 (z0, z1, z2)] =

0.1− .01 (1 + α)× 2z1+z2 , z0 = −1
0.1, if z0 = 0
0.1 + .08 (1 + α)× 2z1+z2 , z0 = 1
. (21)
Proof of relations (6). Since ER [pi (r)] = pi = EY [y] , we have
covY,R [y, pi (r)] = EY,R [ypi (r)]− pi2
= ER
{
EY |R [ypi (r) |r]
}− pi2
= ER
{
[pi (r)]2
}
− pi2 = varR [pi (r)] . (22)
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Also,
σ2 = ER
[
σ2 (r)
]
+ varR [pi (r)] ≥ varR [pi (r)] ,
which implies (6).
Proof of Brier score decomposition (9). We write
BSg = EY,R
[
(y − r)2
]
= EY,R
[
(y − pi (r) + pi (r)− r)2
]
= EREY |R
[
(y − pi (r))2
]
+ 2ER
{
[pi (r)− r]EY |R [y − pi (r)]
}
+ER
[
(pi (r)− r)2
]
. (23)
Here
EY |R
[
(y − pi (r))2
]
= EP |REY |P
[
y − 2ypi (r) + pi2 (r)]
= EP |R [p− 2ppi (r)] + pi2 (r)
= pi (r)− pi2 (r) .
Thus the first summand in (23) is
EREY |R
[
(y − pi (r))2
]
= ER [pi (r)]− ER
[
pi2 (r)
]
= pi − pi2 − var [pi (r)] . (24)
The second summand in (23) vanishes, since
EY |R [y − pi (r)] = EP |REY |P [y − pi (r)] = EP |R [p− pi (r)] = 0. (25)
Substituting (24) and (25) into (23) gives (9).
Proof of equation (18). By the standard decomposition of a variance into the
expectation of a conditional variance plus the variance of a conditional expectation, we
have
varR1,R2 {pi (r1, r2)} = ER1
[
varR1,R2|R1 {pi (r1, r2) |r1}
]
+ varR1 {E [pi (r1, r2) |r1]}
= varR1 {pi (r1)}+ ER1
[
varR1,R2|R1 {pi (r1, r2) |r1}
]
. (26)
This gives (18).
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Plate 1. Two extreme distributions for a population with outcome prevalence 10%. a) all individuals have 
common risk of =10%, so that the risk variance is ²=0. b) ninety percent of individuals have risk 0 and the 
remaining ten percent have risk one. The variance of risks is ²=.10×(1-.10)=.09.
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Plate 2. Risk distributions for two hypothetical populations, A and B. Risks depend on four covariates.  
Panels (a) and (b) show the distributions of true risk, with mean =10%. The standard deviation of true 
risks is 5.4% for population A and 16.7% for Population B.  Panels (c) and (d) show the distributions of 
outcome prevalences in subgroups determined by a risk model based on two of the four covariates 
(Model 1).  Panels (e) and (f) show outcome prevalences in subgroups obtained by expanding Model 1 
with an additional covariate (Model 2). (See Appendix for details). 
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Plate 3. Panel (a) gives an attribute diagram for a model that uses 
two of the four covariates to partition Population B into five risk 
groups, and then assigns each group the outcome prevalence
observed in Population A. Panel (b) shows the attribute diagram 
obtained when this model is expanded to include an additional 
covariate, and again is well calibrated to Population A and applied to 
Population B.
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Plate 4. Cartoon showing how Population B is partitioned into the five risk groups of Model 1 and the seven risk 
groups of Model 2. Also shown is the partition induced by the cross-classified model consisting of individuals 
assigned a common risk by each of the two models. Risk groups are labeled with their outcome prevalences. 
ri
s
k
 
(
%
)
cross-classified risk group
Plate 5. Outcome prevalences and assigned risks in subgroups determined by 
the cross-classified model for Models 1 and 2 when both models are 
calibrated to Population A and applied to Population B.    
 
Table 1. Precision Measures (%) for Risks of Figure 1 
 
 
 Variance of  
Outcome Prevalences 
Precision Loss Risk Outcome Correlation Concordance 
 Population A / Population B Population A / Population B Population A / Population B Population A / Population B 
Model 1 ª 0.24 / 2.57 8.76 / 6.43 16.3 / 53.4 59.4 / 80.6 
Model 2 0.27 / 2.70 8.73 / 6.30 17.2 / 54.7 59.9 / 82.1 
Model Pb 0.30 / 2.83 8.70 / 6.17 18.1 / 56.1 60.3 / 83.3 
 
 
a) risks assigned using covariates 1z  of equation (20) (Model 1) or covariates 2  of equation (21) (Model 2) 0 ,z
b) each individual is assigned his true risk given by equation (19) 
0 1, ,z z z
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Range and Standard Deviation (SD) of Cross-classified Outcome 
Prevalences B ª, by Risk Group of Model 1 
 
 
Model 1  
Risk 
Group 
Outcome  
Prevalences (%) 
Cross-classified Outcome 
Prevalences (%) 
  Range SD 
1   3.5     2.8-6.4  1.4 
2   6.8     6.4-8.2   0.7 
3 10.0 10.0-10.0      0 
4 35.9 24.4-38.8   5.8 
5 61.8 38.8-67.6 11.5 
 
 
a) outcome prevalences in those assigned common risks by Models 1  
      and 2, as shown in panels (d) and (f) of Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Ten-year Prevalences (%) of Postmenopausal ER+ Breast Cancer ª,  
cross-classified by Risk Decile of Model 1 (without Estradiol) and Model 2 (with Estradiol) 
 
 
Model 1  
Risk Decile 
Model 2  
Risk Decile 
Cross-classified 
Prevalences 
               
 1 2 3 4 5 6 7 8 9 10  All Range SD 
1 0.7 1.0 - - - - - - - -  0.7 0.7-1.0 0.12 
2 0.7 0.8 2.0 2.9 - - - - - -  1.1 0.7-2.9 0.62 
3 - 0.5 1.3 1.7 2.2 - - - - -  1.2 0.5-2.2 0.49 
4 - 0.4 1.0 1.3 2.3 3.6 - - - -  1.5 0.4-3.6 0.72 
5 - - 1.4 0.7 1.5 2.7 6.1 - - -  1.8 0.7-6.1 1.16 
6 - - - 1.0 1.1 1.5 3.0 5.2 - -  1.9 1.0-5.2 9.50 
7 - - - - 0.6 1.2 2.1 2.6 6.5 -  2.0 0.6-6.5 8.20 
8 - - - - - 1.6 1.7 2.4 4.8 -  2.7 1.6-4.8 1.13 
9 - - - - - - 2.8 1.5 3.0 5.7  3.1 1.5-5.7 1.24 
10 - - - - - - - - 1.9 4.8  4.4 1.9-4.8 1.06 
               
All 0.7 0.8 1.4 1.4 1.6 1.8 2.4 2.4 3.3 5.0  - - - 
 
 
 
a) from Rosner et al (2008) 
 
 
 
